Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene

Cancer

Volumn 118, Issue 21, 2012, Pages 5217-5226

  Xu, Bin ^a   Zheng, Wen Yan ^b   Jin, Da Yong ^b   Wang, Dan Song ^b   Liu, Xin Yuan ^c   Qin, Xin Yu ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

cancer targeting gene virotherapy; lipocalin 2; oncolytic adenovirus; pancreatic cancer

Indexed keywords

CASPASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOLYTIC ADENOVIRUS; PLASMID VECTOR; PROCASPASE 3; VIRUS PROTEIN;

ADENOVIRUS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; CYTOPATHOGENIC EFFECT; DRUG POTENCY; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPOCALIN 2 GENE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PORTAL VEIN; PREDICTION; PRIORITY JOURNAL; SPLENECTOMY; TUMOR VOLUME; VEIN RECONSTRUCTION; VEIN SURGERY;

ACUTE-PHASE PROTEINS; ADENOVIRIDAE; AGED; FEMALE; GENETIC THERAPY; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; MUTATION; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84867876122     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27535     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Yu X, Zhang Y, Chen C, et al. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta. 2010; 1805: 97-104.
3. Orr RK,. Outcomes in pancreatic cancer surgery. Surg Clin North Am. 2010; 90: 219-234.
4. Hu J, Zhao G, Wang HX, et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma [serial online]. J Hematol Oncol. 2011; 4: 11.
5. Gros A, Puig C, Guedan S, et al. Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther. 2010; 18: 903-911.
6. Ouyang H, Wang P, Meng Z, et al. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas. 2011; 40: 120-125.
7. Cascinu S, Falconi M, Valentini V, et al. Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v55-v58.
8. Nelson AR, Davydova J, Curiel DT, et al. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci. 2009; 100: 2181-2187.
9. Kondo N, Tsukuda M, Kimura M, et al. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncol Rep. 2010; 23: 355-363.
10. Liu XY,. Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 2006; 16: 879-886.
11. Pei Z, Chu L, Zou W, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology. 2004; 39: 1371-1381.
12. Cao X, Yang M, Wei RC, et al. Cancer targeting gene-viro-therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Ther. 2011; 18: 765-777.
13. Qian W, Liu J, Tong Y, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis, Leukemia. 2008; 22: 361-369.
14. Zhang Y, Gu J, Zhao L, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res. 2006; 66: 4291-4298.
15. Liu XY, Qiu SB, Zou WG, et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther. 2005; 11: 531-541.
16. Gounaris I, Zaki K, Corrie P,. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP. 2010; 11: 113-123.
17. Hidalgo M,. Pancreatic cancer. N Engl J Med. 2010; 362: 1605-1617.
18. Rogosnitzky M, Danks R,. Validation of blood testing for K-ras mutations in colorectal and pancreatic cancer. Anticancer Res. 2010; 30: 2943-2947.
19. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101: 1308-1324.
20. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-1634.
21. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26: 374-379.
22. Hanai J, Mammoto T, Seth P, et al. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells, J Biol Chem. 2005; 280: 13641-13647.
23. Venkatesha S, Hanai J, Seth P, et al. Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res. 2006; 4: 821-829.
24. Lin HH, Li WW, Lee YC, et al. Apoptosis induced by uterine 24p3 protein in endometrial carcinoma cell line. Toxicology. 2007; 234: 203-215.
25. Park S, Guo J, Kim D, et al. Identification of 24p3 as a direct target of Foxo3a regulated by interleukin-3 through the phosphoinositide 3-kinase/Akt pathway. J Biol Chem. 2009; 284: 2187-2193.
26. Bousserouel S, Lamy V, Gosse F, et al. Early modulation of gene expression used as a biomarker for chemoprevention in a preclinical model of colon carcinogenesis. Pathol Int. 2011; 61: 80-87.
27. Bousserouel S, Gosse F, Bouhadjar M, et al. Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep. 2010; 23: 511-517.
28. Rommelaere J, Geletneky K, Angelova AL, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 2010; 21: 185-195.
29. Kasuya H, Takeda S, Nomoto S, et al. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther. 2005; 12: 725-736.
30. Zhang ZL, Zou WG, Luo CX, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 2003; 13: 481-489.
31. Boisgerault N, Tangy F, Gregoire M,. New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy. 2010; 2: 185-199.
32. Hartkopf AD, Fehm T, Wallwiener D, et al. Oncolytic virotherapy of gynecologic malignancies. Gynecol Oncol. 2011; 120: 302-310.
33. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003; 9: 555-561.
34. He XP, Su CQ, Wang XH, et al. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett. 2009; 285: 89-98.
35. Carlson SK, Classic KL, Hadac EM, et al. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol. 2009; 192: 279-287.
36. Ramirez PJ, Vickers SM, Ono HA, et al. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg. 2008; 195: 481-490.
37. Watanabe I, Kasuya H, Nomura N, et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol. 2008; 61: 875-882.
38. Lee HJ, Lee EK, Lee KJ, et al. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer. 2006; 118: 2490-2497.
39. Tong Z, Kunnumakkara AB, Wang H, et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008; 68: 6100-6108.
40. Tong Z, Chakraborty S, Sung B, et al. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells [published online ahead of print December 29, 2010]. Cancer. 2010.
41. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010; 39: 425-435.
42. Kato K, Hitomi Y, Imamura K, et al. Hyperstable U1snRNA complementary to the K-ras transcripts induces cell death in pancreatic cancer cells. Br J Cancer. 2002; 87: 898-904.
43. Thaker NG, Pollack IF,. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother. 2009; 9: 1815-1836.
44. Kombos T, Picht T, Derdilopoulos A, et al. Impact of intraoperative neurophysiological monitoring on surgery of high-grade gliomas. J Clin Neurophysiol. 2009; 26: 422-425.
45. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009; 110: 156-162.
46. Yang J, Moses MA,. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009; 8: 2347-2352.
47. Kehrer JP,. Lipocalin-2: pro- or anti-apoptotic? Cell Biol Toxicol. 2010; 26: 83-89.
48. Bolignano D, Donato V, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2010; 288: 10-16.